TEMPUS AI, INC. CLASS A COMMON STOCK

NASDAQ: TEM (Tempus AI, Inc.)

Last update: 19 hours ago

77.03

3.25 (4.40%)

Previous Close 73.78
Open 72.36
Volume 9,478,318
Avg. Volume (3M) 11,979,372
Market Cap 13,382,267,904
Price / Earnings (TTM) 35.83
Price / Sales 13.46
Price / Book 41.41
52 Weeks Range
31.36 (-59%) — 91.45 (18%)
Earnings Date 3 Nov 2025
Profit Margin -88.27%
Operating Margin (TTM) -26.93%
Diluted EPS (TTM) -5.16
Quarterly Revenue Growth (YOY) 75.40%
Total Debt/Equity (MRQ) 262.96%
Current Ratio (MRQ) 1.71
Operating Cash Flow (TTM) -193.29 M
Levered Free Cash Flow (TTM) 54.30 M
Return on Assets (TTM) -43.89%

Market Trend

Short Term Medium Term
Industry Health Information Services (US) Bullish Mixed
Health Information Services (Global) Bullish Mixed
Stock Tempus AI, Inc. Bearish Bullish

AIStockmoo Score

-0.4
Analyst Consensus -5.0
Insider Activity NA
Price Volatility -3.0
Technical Moving Averages 2.5
Technical Oscillators 4.0
Average -0.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TEM 13 B - 35.83 41.41
HQY 8 B - 67.04 3.74
WAY 6 B - 64.71 1.90
RCM 6 B - - 2.14
PRVA 3 B - 191.25 3.78
WGS 3 B - - 10.90

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Sector Healthcare
Industry Health Information Services
Investment Style Small Growth
% Held by Insiders 43.27%
% Held by Institutions 38.33%

Ownership

Name Date Shares Held
Softbank Group Corp. 30 Jun 2025 5,405,406
Sumitomo Mitsui Trust Group, Inc. 30 Jun 2025 3,869,941
Nikko Asset Management Americas, Inc. 30 Jun 2025 3,869,941
Revolution Growth Management Company, Inc. 31 Mar 2025 1,467,565
52 Weeks Range
31.36 (-59%) — 91.45 (18%)
Price Target Range
68.00 (-11%) — 75.00 (-2%)
High 75.00 (Guggenheim, -2.64%) Buy
Median 70.00 (-9.13%)
Low 68.00 (Morgan Stanley, -11.72%) Buy
Average 71.00 (-7.83%)
Total 2 Buy, 1 Hold
Avg. Price @ Call 65.12
Firm Date Target Price Call Price @ Call
Morgan Stanley 12 Aug 2025 68.00 (-11.72%) Buy 66.34
Guggenheim 30 Jun 2025 75.00 (-2.64%) Buy 63.54
B of A Securities 25 Jun 2025 70.00 (-9.13%) Hold 65.47
20 May 2025 68.00 (-11.72%) Hold 62.43

No data within this time range.

Date Type Details
08 Aug 2025 Announcement Tempus Reports Second Quarter 2025 Results
22 Jul 2025 Announcement Tempus to Report Second Quarter 2025 Financial Results on August 8
16 Jul 2025 Announcement Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
16 Jul 2025 Announcement From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine
09 Jul 2025 Announcement Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
08 Jul 2025 Announcement Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
30 Jun 2025 Announcement Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
30 Jun 2025 Announcement Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
25 Jun 2025 Announcement Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
17 Jun 2025 Announcement Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
13 Jun 2025 Announcement Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
12 Jun 2025 Announcement Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
02 Jun 2025 Announcement Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
01 Jun 2025 Announcement Introducing Tempus One in the EHR with Integrated Guidelines
31 May 2025 Announcement Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
30 May 2025 Announcement Real-World Deployments Signal AI Healthcare Is Ready for Scale
30 May 2025 Announcement Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
28 May 2025 Announcement A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
28 May 2025 Announcement Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Tempus AI, Inc. (Nasdaq: TEM)
21 May 2025 Announcement Tempus to Present at the William Blair 45th Annual Growth Stock Conference
21 May 2025 Announcement Options Trading Now Available on Three Tradr ETFs: QBTX, TEMT and APPX
20 May 2025 Announcement Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
20 May 2025 Announcement From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria